90447337 - ITM PASSION FOR PRECISION

Information

• Trademark
• 90447337

• Source

• Serial Number

  90447337

• Registration Number

  6546779

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 10 - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  January 04, 2021
  4 years ago

• Registration Date

  November 02, 2021
  3 years ago

• Transaction Date

  May 19, 2022
  3 years ago

• Status Date

  November 02, 2021
  3 years ago

• Published for Opposition Date

  August 17, 2021
  4 years ago

• Location Date

  November 02, 2021
  3 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  WILKE, JOHN

• Attorney Docket Number

  540.319US

  Attorney Name

  Kari Moyer-Henry

  Law Office Assigned Location Code

  L40

• Owners

  • Isotopen Technologien Munchen AG

Case File Statements

• DM0000: The mark consists of stylized letters "ITM" with two dots coming from the top of the "i" all positioned above the phrase "PASSION FOR PRECISION".
• GS0051: Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography (PET) or single photon emission tomography (SPECT), target radionuclide and peptide receptor radionuclide therapy (PRRT); theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumors; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET); radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; radiopharmaceuticals for use with high-sensitivity molecular imaging technologies such as PET (positron emission tomography) or SPECT (single photon emission tomography), for imaging organs and lesions and for early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumor diseases
• GS0441: Medical services, in particular services in the field of radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapy, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncology
• GS0101: Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; control, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators for radiopharmaceutical purposes
• GS0421: Conducting clinical trials in all stages and with various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)

Case File Event Statements

• 5/19/2022 - 3 years ago

  12 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN

• 11/2/2021 - 3 years ago

  11 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 8/17/2021 - 4 years ago

  10 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 8/17/2021 - 4 years ago

  9 - PUBLISHED FOR OPPOSITION Type: PUBO

• 7/28/2021 - 4 years ago

  8 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 7/13/2021 - 4 years ago

  7 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 7/12/2021 - 4 years ago

  6 - ASSIGNED TO EXAMINER Type: DOCK

• 4/3/2021 - 4 years ago

  5 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC

• 4/2/2021 - 4 years ago

  4 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 1/28/2021 - 4 years ago

  3 - TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED Type: TAEA

• 1/28/2021 - 4 years ago

  2 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI

• 1/7/2021 - 4 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP